FDA Approves LEQVIO — Novartis Pharmaceuticals Corporation

# FDA Approves Novartis's LEQVIO (Inclisiran) for Cholesterol Management The FDA has approved Novartis Pharmaceuticals Corporation's LEQVIO (inclisiran sodium), a groundbreaking subcutaneous treatment that addresses a significant market gap in cardiovascular disease management and positions Novartis to capture share in the high-value cholesterol-lowering drug market. The approval of this innovative LDL-cholesterol-reducing therapy could reshape treatment paradigms for patients with familial hypercholesterolemia and atherosclerotic cardiovascular disease